ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) Current Ratio
- Current ratio · latest quarter: Value 4.79×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 4.79× | Current assets / current liabilities. $420.56M ÷ $87.71M ≈ 4.79× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 420.56M USD | Assets, Current |
| Current obligations | 87.71M USD | Liabilities, Current |
| Cash and equivalents | 169.87M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 174.38M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | 49.51M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 10.50M USD | Inventory, Net |
| Payables | 5.24M USD | Accounts Payable, Current |
| Borrowing debt due within one year | 0.00 USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $420.56M | $87.71M | $169.87M | $174.38M | $49.51M | $10.50M | $5.24M | $0.00 | 4.79× |
| 2026-03-31 | $291.81M | $87.01M | $77.58M | $140.75M | $48.31M | $11.21M | $9.62M | $5.80M | 3.35× |
| 2025-12-31 | $300.19M | $89.92M | $70.50M | $156.49M | $50.37M | $9.82M | $6.47M | $4.64M | 3.34× |
| 2025-09-30 | $281.44M | $83.36M | $55.03M | $157.74M | $44.82M | $9.93M | $10.27M | $2.43M | 3.38× |
| 2025-06-30 | $261.86M | $92.14M | $43.16M | $154.71M | $44.28M | $8.40M | $6.91M | $3.07M | 2.84× |
| 2025-03-31 | $256.49M | $87.81M | $50.65M | $142.78M | $43.58M | $8.68M | $6.36M | $2.01M | 2.92× |
| 2024-12-31 | $283.75M | $98.05M | $47.92M | $174.37M | $41.73M | $8.44M | $7.26M | $865.00K | 2.89× |
| 2024-09-30 | $308.35M | $87.63M | $38.08M | $205.25M | $40.81M | $11.96M | $7.35M | (m) | 3.52× |
| 2024-06-30 | $351.55M | $88.13M | $59.82M | $232.06M | $35.61M | $13.21M | $9.87M | (m) | 3.99× |
| 2024-03-31 | $374.03M | $82.95M | $71.23M | $237.64M | $42.02M | $13.29M | $12.17M | (m) | 4.51× |
| 2023-12-31 | $410.19M | $88.02M | $65.06M | $281.34M | $37.97M | $14.45M | $7.72M | (m) | 4.66× |
| 2023-09-30 | $435.24M | $93.30M | $88.71M | $282.42M | $31.21M | $19.49M | $4.48M | $3.19M | 4.67× |
| 2023-06-30 | $476.81M | $95.33M | $109.24M | $307.99M | $31.55M | $18.96M | $9.16M | (m) | 5.00× |
| 2023-03-31 | $501.33M | $90.10M | $94.61M | $346.08M | $30.97M | $19.87M | $6.33M | (m) | 5.56× |
| 2022-12-31 | $562.15M | $109.79M | $90.03M | $408.17M | $40.06M | $14.45M | $8.08M | (m) | 5.12× |
| 2022-09-30 | $564.38M | $104.02M | $217.55M | $290.53M | $26.55M | $17.34M | $4.16M | (m) | 5.43× |
| 2022-06-30 | $438.57M | $111.47M | $76.41M | $307.33M | $23.71M | $18.78M | $2.72M | (m) | 3.93× |
| 2022-03-31 | $419.12M | $115.07M | $114.81M | $248.76M | $22.52M | $21.00M | $5.96M | (m) | 3.64× |
| 2021-12-31 | $402.75M | $113.81M | $139.06M | $214.00M | $17.41M | $19.26M | $3.31M | (m) | 3.54× |
| 2021-09-30 | $467.03M | $122.38M | $122.40M | $292.64M | $17.12M | $18.23M | $8.25M | (m) | 3.82× |
| 2021-06-30 | $643.73M | $116.65M | $184.19M | $414.23M | $14.17M | $18.61M | $6.09M | (m) | 5.52× |
| 2021-03-31 | $764.96M | $106.77M | $173.62M | $540.64M | $19.75M | $17.42M | $5.20M | (m) | 7.16× |
| 2020-12-31 | $726.91M | $105.20M | $123.44M | $564.83M | $10.05M | $14.06M | $3.24M | (m) | 6.91× |
| 2020-09-30 | $877.36M | $100.83M | $497.08M | $338.00M | $11.86M | $10.74M | $5.41M | (m) | 8.70× |
| 2020-06-30 | $599.52M | $93.42M | $365.44M | $204.94M | $7.91M | $10.54M | $3.69M | (m) | 6.42× |
| 2020-03-31 | $584.65M | $77.95M | $212.69M | $342.49M | $9.38M | $10.52M | $3.90M | (m) | 7.50× |
| 2019-12-31 | $612.69M | $78.31M | $96.58M | $480.29M | $12.68M | $9.07M | $4.45M | (m) | 7.82× |
| 2019-09-30 | $601.36M | $73.38M | $74.94M | $498.49M | $9.26M | $8.67M | $2.42M | (m) | 8.20× |
| 2019-06-30 | $442.30M | $74.86M | $48.46M | $374.54M | $7.25M | $8.00M | $2.94M | (m) | 5.91× |
| 2018-12-31 | $180.72M | $22.80M | $55.03M | $109.99M | $4.81M | $7.84M | $1.79M | (m) | 7.93× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |